Amisulpride-Induced Neuroleptic Malignant Syndrome

Abay, Ercan; Kose, Rugul

doi:10.1176/jnp.2007.19.4.488

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite several decades of amisulpride use, only seven cases of amisulpride-induced NMS (AMI-NMS) have been described [8, 54–59]. Most cases occurred in older males.…”

Section: Discussionmentioning

confidence: 99%

“…These observations led to the hypothesis that ‘atypical’ antipsychotics might determine ‘atypical’ forms of NMS on the basis of different pharmacological properties [6]. Furthermore, newer SGAs such as aripiprazole [7] and amisulpride [8] possess peculiar pharmacodynamic profiles [9, 10] which might be associated with different NMS presentation. At present, while it is commonly accepted that no antipsychotic is free from the risk of inducing NMS, there is still uncertainty on the clinical profile of SGA-NMS [6, 11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

et al. 2015

View full text Add to dashboard Cite

BackgroundNeuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse reaction to antipsychotics. Second-generation antipsychotics (SGAs) were originally assumed to be free from the risk of causing NMS, however several cases of NMS induced by SGAs (SGA-NMS) have been reported.ObjectivesThe aim of this study was to systematically review available studies and case reports on SGA-NMS and compare the presentation of NMS induced by different SGAs.Data SourcesCitations were retrieved from PubMed up to November 2013, and from reference lists of relevant citations.Study Eligibility CriteriaEligibility criteria included (a) primary studies reporting data on NMS, with at least 50 % of the sample receiving SGAs; or (b) case reports and case reviews reporting on NMS induced by SGA monotherapy, excluding those due to antipsychotic withdrawal.Study Appraisal and Synthesis MethodsA standardized method for data extraction and coding was developed for the analysis of eligible case reports.ResultsSix primary studies and 186 individual cases of NMS induced by SGAs were included. Primary studies suggest that SGA-NMS is characterized by lower incidence, lower clinical severity, and less frequent lethal outcome than NMS induced by first-generation antipsychotics. Systematic analysis of case reports suggests that even the most recently marketed antipsychotics are not free from the risk of inducing NMS. Furthermore, clozapine-, aripiprazole- and amisulpride-induced NMS can present with atypical features more frequently than other SGA-NMS, i.e. displaying less intense extrapyramidal symptoms or high fever.LimitationsCase reports report non-systematic data, therefore analyses may be subject to bias.Conclusions and Implications of Key FindingsClinicians should be aware that NMS is virtually associated with all antipsychotics, including those most recently marketed. Although apparently less severe than NMS induced by older antipsychotics, SGA-NMS still represent a relevant clinical issue.Electronic supplementary materialThe online version of this article (doi:10.1007/s40268-014-0078-0) contains supplementary material, which is available to authorized users.

show abstract

“…Despite several decades of amisulpride use, only seven cases of amisulpride-induced NMS (AMI-NMS) have been described [8, 54–59]. Most cases occurred in older males.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The underlying pathophysiological mechanisms of NMS are still vague, 3 and those caused by antipsychotics are often associated with its impact on dopamine in the mesocortical‐nigrostriatal pathways and the hypothalamic nuclei 3 . As shown by previous studies, the incidence rate of NMS has had a downward trend over the recent years, due to the growth in the prescription of atypical antipsychotic drugs compared to the typical ones, reaching 0.01%–0.02% in cases undergoing treatment, and even 0.07%–3.22% in some reports 1–4 . On the contrary, malnutrition, dehydration, iron deficiency, exposure to extreme heat, hyponatremia, and thyrotoxicosis have been characterized to increase the risk of this condition 5 .…”

Section: Introductionmentioning

confidence: 99%

“… 3 As shown by previous studies, the incidence rate of NMS has had a downward trend over the recent years, due to the growth in the prescription of atypical antipsychotic drugs compared to the typical ones, reaching 0.01%–0.02% in cases undergoing treatment, and even 0.07%–3.22% in some reports. 1 , 2 , 3 , 4 On the contrary, malnutrition, dehydration, iron deficiency, exposure to extreme heat, hyponatremia, and thyrotoxicosis have been characterized to increase the risk of this condition. 5 The mortality rate caused by NMS had been already estimated to be over 30%.…”

Section: Introductionmentioning

confidence: 99%

The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID‐19 pandemic: A significant increase in acute phase reactants

Elyasi,

Zarghami,

Fariborzifar

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageIn some patients, neuroleptic malignant syndrome is accompanied significant high levels of erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP).AbstractNeuroleptic malignant syndrome (NMS) is an idiosyncratic life‐threatening adverse reaction and usually triggered in response to antipsychotic drugs. In addition, leukocytosis and increased muscle enzymes levels (especially creatine phosphokinase) are observed in NMS. In addition, a transient increase in different types of acute phase reactants in NMS has been mentioned. This article describes a woman treated with haloperidol, perphenazine, escitalopram, and alprazolam because she developed catatonic symptoms after psychological stress. She suffered from NMS symptoms and had elevated CRP and ESR levels, among other signs and symptoms. Given the COVID‐19 pandemic and reports of co‐occurrence of catatonia and NMS and COVID‐19 and elevated erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP), this patient was a diagnostic dilemma. After consultation with the consultation‐liaison psychiatry units, she was managed adequately with electroconvulsive therapy and lorazepam.

show abstract

Syndrome malin des neuroleptiques sous amisulpride chez une patiente lors d’un deuxième accès psychotique

Barrimi¹,

Ghazouani²,

Zaimi³

et al. 2018

La Presse Médicale

View full text Add to dashboard Cite

Amisulpride-Induced Neuroleptic Malignant Syndrome

Cited by 3 publications

References 5 publications

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID‐19 pandemic: A significant increase in acute phase reactants

Syndrome malin des neuroleptiques sous amisulpride chez une patiente lors d’un deuxième accès psychotique

Contact Info

Product

Resources

About